VANGUARD® CIV vaccines have been field tested for safety.
VANGUARD CIV H3N2/H3N86
Study group: A total of 364 dogs;* 200 located at commercial breeding facilities and 164 client-owned dogs; 116 dogs were 8 weeks of age or younger, 245 were 9 weeks of age or older.
- No significant adverse event (AEs) attributed to vaccination were observed
- Evaluation immediately after vaccination (725 doses): vocalization† (1.0%), paresthesia (0.4%), injection site edema (0.1%) and lethargy (0.1%)
- The most frequently observed AEs reported through 10 days after the second vaccination were vomiting (0.83%) and diarrhea (0.83%)‡
*Three dogs were removed from the study. Reasons for removal: two cases of non-compliance with the schedule; the other had a non-related adverse health event. No dogs were removed for reasons related to the vaccine.
†Vocalization was only seen in the dogs who were 8 weeks of age or younger at the time of first vaccination.
‡Majority of the late abnormal health events reported occurred in three dogs after the first vaccination and were deemed unrelated to vaccination; one dog was hit by a car, one dog had dietary indiscretion and one dog had a non-related medical condition.